Figure 5.

Dose-dependent activity of LHR domain combination variants in vitro. The indicated CR1 LHR domain variants (Fig. 1) were tested in the following complement assays: the Wieslab classical (A), lectin (B), and alternative (C) pathways assays; and the red blood cell hemolytic assays specific for the classical (D) and alternative (E) pathways (CH50 and ApH50 assays, respectively). CSL040 containing LHR-ABC was used as a control/comparator. IC₅₀ values calculated from these data are shown in Table 4. CR1, complement receptor 1; LHR, long homologous repeat.